%0 Journal Article
%T Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?
%A Kaplan SA
%A Roehrborn CG
%A Hill LA
%A Volinn W
%J Open Access Journal of Urology
%D 2011
%I 
%X Steven A Kaplan1, Claus G Roehrborn2, Lawrence A Hill3, Weining Volinn31Weill College of Medicine Cornell University, New York, NY, USA; 2University of Texas Southwestern Medical Center, Dallas, TX, USA; 3Watson Laboratories Inc., Salt Lake City, UT, USAObjective: The uroselective ¦Á-blocker silodosin significantly improved International Prostate Symptom Score (IPSS) in two 12-week, double-blind (DB), placebo-controlled Phase III studies in men aged ¡Ý 50 years with symptoms of benign prostatic hyperplasia (BPH) and maintained symptom improvement during a 9-month open-label (OL) extension. This post-hoc analysis evaluated the effects of estimated prostate volume (EPV) on silodosin-mediated symptom improvement.Methods: Patients were stratified by EPV (<30 mL or ¡Ý 30 mL) calculated from prostate-specific antigen (PSA) concentrations using a published algorithm. Group comparisons were done by analysis of covariance with last observations carried forward.Results: Of 890 patients with PSA baseline data, 192 had EPV < 30 mL and 698 had EPV ¡Ý 30 mL. During DB treatment, silodosin was associated with significant symptom improvement (adjusted mean difference versus placebo) in men with EPV < 30 mL (-2.0; P = 0.038) and those with EPV ¡Ý 30 mL (-3.0; P < 0.0001). Among patients who received silodosin during DB treatment, changes from baseline in IPSS to the end of OL extension (mean ¡À standard deviation) were similar for EPV < 30 mL (n = 60, -7.0 ¡À 6.8) and EPV ¡Ý 30 mL (n = 242, -8.0 ¡À 7.1; P = 0.416). Also, among patients who received placebo as DB treatment, symptom improvement at the end of OL extension was similar for EPV < 30 mL (n = 62, -6.2 ¡À 8.1) and EPV ¡Ý 30 mL (n = 275, -6.7 ¡À 6.1; P = 0.339).Conclusion: Silodosin effectively relieved BPH-related symptoms for up to 12 months, irrespective of prostate size, including in patients with enlarged prostates.Keywords: International Prostate Symptom Score, IPSS, benign prostatic hyperplasia
%U http://www.dovepress.com/effect-of-estimated-prostate-volume-on-silodosin-mediated-improvements-a7616